Clinical trials: Sunitinib
Cancer, High-grade Glioma
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue (in the brain) of patients with high-grade gliomas (HGG).
- Trial name
- NCT02239952
- Testing
- Sunitinib, vandetanib, Erlotinib
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Amsterdam UMC, location VUmc
GIST
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)
The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST) resistant to imatinib and sunitinib.
- Trial name
- PAZOGIST (NCT01323400)
- Testing
- Pazopanib, Best supportive care
- Where
- 13 sites in France
- Volunteers
- 81 people
- Sponsor
- Centre Leon Berard
Metastatic Renal Cell Carcinoma, Kidney Cancer
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
The purpose of this study is to test the safety of bevacizumab and sunitinib given in combination for kidney cancer. The drugs act to stop blood vessel growth but in different ways.
- Trial name
- NCT00421512
- Testing
- Bevacizumab and Sunitinib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01158222
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Esophageal Cancer
Sutent + Taxol for Advanced Esophageal Cancer
Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens.
- Trial name
- NCT00730353
- Testing
- Sunitinib malate, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 28 people
- Sponsor
- Hoosier Cancer Research Network
Neoplasms
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin. This combination regimen will be tested for safety and antitumor activity.
- Trial name
- NCT00511849
- Testing
- carboplatin + SU011248 (sunitinib) + paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Pfizer
Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
This phase II trial is studying how well sunitinib works in treating patients with recurrent or persistent leiomyosarcoma of the uterus.
- Trial name
- NCT00378911
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors
Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
The objective of the trial is to provide regorafenib to subjects diagnosed with metastatic and / or unresectable GIST who have progressed after standard therapy.
- Trial name
- NCT01646593
- Testing
- Regorafenib (BAY73-4506)
- Sponsor
- Bayer
Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00748163
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, sunitinib malate
- Sponsor
- Masonic Cancer Center, University of Minnesota
Kidney Cancer
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00717587
- Testing
- motexafin gadolinium, sunitinib malate, comparative genomic hybridization
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Neuroendocrine Tumors, Pancreatic Neoplasms
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
The purpose of this study is to identify predictive molecular markers of response to continuous daily sunitinib at dose of 37.5 mg used in patients with poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.
- Conditions
- Neuroendocrine Tumors, Pancreatic Neoplasms, Advanced Disease, Sunitinib
- Trial name
- NET (NCT01215578)
- Testing
- Sutent
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Cancer
Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- SURTIME (NCT01099423)
- Testing
- timing of surgery, gene expression analysis, biologic sample preservation procedure
- Where
- 29 sites in Belgium, Canada and 3 more
- Volunteers
- 99 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Renal Cell Carcinoma
Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques
Prospective observational study to assess bone predictive biomarkers for TKI response in RCC patients with bone metastasis and HRQoL with TKI in these patients as well as the sensitivity and specificity of whole body magnetic…
- Trial name
- METHEOS (NCT02747173)
- Where
- 12 sites in Spain
- Volunteers
- 4 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
This phase I trial is studying the side effects and best way to give sunitinib malate in treating patients with unresectable or metastatic kidney cancer or other advanced solid tumors.
- Conditions
- Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer
- Trial name
- NCT00499135
- Testing
- Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
This trial has two parts. The purpose of the first part of the trial is to determine the doses of 2 drugs, sunitinib malate and interferon alfa-2b, that can be given safely in combination.
- Trial name
- NCT00267748
- Testing
- Sunitinib Malate Continuous Daily Dosing, Sunitinib Malate Schedule 4/2
- Where
- 156 sites in United States
- Volunteers
- 317 people
- Sponsor
- Pfizer
Advanced Rare Tumours
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.
- Trial name
- NCT01396408
- Testing
- Sunitinib, Temsirolimus
- Where
- 17 sites in Canada
- Volunteers
- 137 people
- Sponsor
- Canadian Cancer Trials Group
Non-Small Cell Lung Cancer
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
This is a Phase II, randomized, controlled, open-label, multicenter trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with carboplatin and paclitaxel chemotherapy and…
- Trial name
- NCT00434226
- Testing
- bevacizumab, sunitinib, carboplatin
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.
Renal Cell Cancer
Temsirolimus-RCC-imaging
This study uses one trialdrug: Temsirolimus (sometimes called Torisel ® ). Temsirolimus is an mTOR inhibitor. It is an agent that is specifically aimed at disrupting cell division (needed for cancer cell growth).
- Trial name
- NCT01246817
- Testing
- Temsirolimus
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- Radboud University Medical Center
Breast Neoplasms
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.
- Trial name
- NCT00471276
- Testing
- sunitinib
- Where
- 31 sites in United States
- Volunteers
- 83 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged…
- Trial name
- NCT05245968
- Testing
- Pimitespib, Imatinib, Sunitinib
- Where
- 14 sites in Australia, China and 3 more
- Volunteers
- 78 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.